Table 2. Association of rs9393682 with disease progression in localized prostate cancer patients treated with RP.

SNP	Univariate analysis										Multivariate analysisa
Genotype	Discovery				Replication				Combined		Discovery		Replication		Combined
	N	Prog	HR (95% CI)	P	N	Prog	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
rs9393682
TT	47	8	1.00		45	14	1.00		1.00		1.00		1.00		1.00
TC	59	20	2.65 (1.11-6.29)	0.03	79	31	1.37 (0.73-2.59)	0.33	1.72 (1.03-2.86)	0.04	1.65 (0.57-4.79)	0.36	1.23 (0.63-2.41)	0.55	1.34 (0.76-2.36)	0.31
CC	35	13	3.82 (1.51-9.63)	0.005	38	26	2.83 (1.47-5.43)	0.002	3.13 (1.83-5.34)	< 0.001	3.53 (1.21-10.3)	0.02	1.76 (0.88-3.51)	0.11	2.16 (1.21-3.87)	0.009
TC/CC vs TT			3.01 (1.32-6.84)	0.009			1.79 (1.00-3.23)	0.05	2.13 (1.32-3.42)	0.002	2.26 (0.84-6.10)	0.11	1.43 (0.77-2.66)	0.26	1.63 (0.96-2.75)	0.07
CC vs TT/TC			2.05 (1.05-3.98)	0.04			2.30 (1.42-3.73)	0.001	2.21 (1.50-3.27)	< 0.001	2.50 (1.21-5.15)	0.01	1.53 (0.91-2.58)	0.11	1.81 (1.18-2.76)	0.006
Trend			1.87 (1.23-2.86)	0.004			1.74 (1.24-2.42)	0.001	1.79 (1.38-2.33)	< 0.001	1.94 (1.15-3.26)	0.01	1.34 (0.95-1.89)	0.10	1.50 (1.12-2.00)	0.006

Abbreviations: RP, radical prostatectomy; SNP, single nucleotide polymorphism; Prog, progression; HR, hazard ratio; 95% CI, 95% confidence interval; PSA, prostate-specific antigen.

^aAdjusted by age, PSA at diagnosis, pathologic Gleason score, and pathologic stage.

P < 0.05 are in boldface.